Thrombospondin 2 (TSP2) and SPARC are matricellular proteins that act as extracellular regulators of cellular function. These proteins modulate the shape and adhesion, and the migratory, synthetic and proliferative activities of a variety of cells. As a consequence, mice that lack TSP2 and SPARC as a result of targeted mutations of the endogenous genes display abnormalities in a wide variety of fundamental biological characteristics and processes, including the composition and structure of the extracellular matrix, the response to injury, bone growth, blood vessel development and growth, and hemostasis. The focus of this application is the regulation of vascular growth by matricellular proteins. Experiments to answer the following questions will therefore be designed. 1) What is the molecular basis for the mode of action of action of TSP2 as a inhibitor of angiogenesis? 2) Do SPARC-null mice exhibit abnormal angiogenesis and/or vasculogenesis? 3.) Does the SPARC homolog, SC1, compensate partially or fully for SPARC in the morphogenesis of the vasculature in SPARC-null mice? 4) Will phenotypes relating to vasculature, or to connective tissue, be exacerbated in mice lacking two inhibitors of angiogenesis, TSP2 & SPARC? The answers to these questions will provide important new information regarding the control of blood vessel formation. In addition, these experiments have the potential to develop a means by which the healing of skin wounds can be improved, and the foreign body reaction to implanted biomaterials modified, such that the normally avascular capsule is vascularized.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
2P01HL018645-26
Application #
6353046
Study Section
Project Start
2000-09-30
Project End
2001-08-31
Budget Start
Budget End
Support Year
26
Fiscal Year
2000
Total Cost
$266,433
Indirect Cost
Name
University of Washington
Department
Type
DUNS #
135646524
City
Seattle
State
WA
Country
United States
Zip Code
98195
Wight, Thomas N (2018) A role for proteoglycans in vascular disease. Matrix Biol 71-72:396-420
Kocarnik, Beverly M; Boyko, Edward J; Matsumoto, Alvin M et al. (2016) Baseline estradiol concentration in community-dwelling Japanese American men is not associated with intra-abdominal fat accumulation over 10 years. Obes Res Clin Pract 10:624-632
Nishizawa, Tomohiro; Kanter, Jenny E; Kramer, Farah et al. (2014) Testing the role of myeloid cell glucose flux in inflammation and atherosclerosis. Cell Rep 7:356-365
Wight, Thomas N; Kinsella, Michael G; Evanko, Stephen P et al. (2014) Versican and the regulation of cell phenotype in disease. Biochim Biophys Acta 1840:2441-51
Kang, Inkyung; Yoon, Dong Won; Braun, Kathleen R et al. (2014) Expression of versican V3 by arterial smooth muscle cells alters tumor growth factor ? (TGF?)-, epidermal growth factor (EGF)-, and nuclear factor ?B (NF?B)-dependent signaling pathways, creating a microenvironment that resists monocyte adhesion. J Biol Chem 289:15393-404
Ruppert, S M; Hawn, T R; Arrigoni, A et al. (2014) Tissue integrity signals communicated by high-molecular weight hyaluronan and the resolution of inflammation. Immunol Res 58:186-92
Wight, Thomas N; Kang, Inkyung; Merrilees, Mervyn J (2014) Versican and the control of inflammation. Matrix Biol 35:152-61
Tsubota, Yoshiaki; Frey, Jeremy M; Tai, Phillip W L et al. (2013) Monocyte ADAM17 promotes diapedesis during transendothelial migration: identification of steps and substrates targeted by metalloproteinases. J Immunol 190:4236-44
Cieslewicz, Maryelise; Tang, Jingjing; Yu, Jonathan L et al. (2013) Targeted delivery of proapoptotic peptides to tumor-associated macrophages improves survival. Proc Natl Acad Sci U S A 110:15919-24
Lund, Susan Amanda; Wilson, Carole L; Raines, Elaine W et al. (2013) Osteopontin mediates macrophage chemotaxis via ?4 and ?9 integrins and survival via the ?4 integrin. J Cell Biochem 114:1194-202

Showing the most recent 10 out of 632 publications